Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 395.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,508 shares of the company’s stock after buying an additional 43,499 shares during the period. Barclays PLC owned about 0.09% of Monte Rosa Therapeutics worth $289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Wellington Management Group LLP lifted its position in shares of Monte Rosa Therapeutics by 30.2% during the 3rd quarter. Wellington Management Group LLP now owns 217,001 shares of the company’s stock valued at $1,150,000 after buying an additional 50,330 shares in the last quarter. State Street Corp lifted its position in shares of Monte Rosa Therapeutics by 8.1% during the 3rd quarter. State Street Corp now owns 687,577 shares of the company’s stock valued at $3,644,000 after buying an additional 51,493 shares in the last quarter. Ikarian Capital LLC purchased a new position in shares of Monte Rosa Therapeutics during the 3rd quarter valued at approximately $1,651,000. Vestal Point Capital LP lifted its position in shares of Monte Rosa Therapeutics by 4.5% during the 3rd quarter. Vestal Point Capital LP now owns 930,000 shares of the company’s stock valued at $4,929,000 after buying an additional 40,000 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Monte Rosa Therapeutics by 54.5% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 24,100 shares of the company’s stock valued at $128,000 after buying an additional 8,500 shares in the last quarter. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Wells Fargo & Company lowered Monte Rosa Therapeutics from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $14.00 to $11.00 in a report on Thursday, December 19th. Wedbush restated an “outperform” rating and issued a $15.00 price objective on shares of Monte Rosa Therapeutics in a report on Thursday, November 7th.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock opened at $7.17 on Monday. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $12.40. The firm has a market capitalization of $440.52 million, a P/E ratio of -3.92 and a beta of 1.37. The stock’s fifty day moving average is $8.40 and its two-hundred day moving average is $6.17.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.16. The business had revenue of $9.22 million for the quarter, compared to analyst estimates of $4.54 million. On average, equities analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, major shareholder Versant Venture Capital Vi, L. sold 89,990 shares of Monte Rosa Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $9.66, for a total value of $869,303.40. Following the completion of the transaction, the insider now directly owns 2,007,948 shares of the company’s stock, valued at $19,396,777.68. The trade was a 4.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 6.50% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.